- Labopharm's Canadian Marketing Partner, Paladin, Enters Into Co-
Promotion Agreement with Nycomed Canada -
LAVAL, QC, Feb. 1 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS, NASDAQ: DDSS) today announced that its Canadian licensing and distribution partner for its once-daily tramadol product (Tridural(TM)), Paladin Labs Inc. (TSX: PLB), has entered into a co-promotion agreement for Tridural(TM) with Nycomed Canada Inc. The agreement will double the number of primary care sales representatives promoting Tridural(TM) in Canada.
"The addition of Nycomed's sales force to that of Paladin will significantly expand the marketing and sales effort behind our product," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We are very pleased with the continued penetration of Tridural(TM) into the Canadian pain market. While still relatively early in the launch, growth indicators and feedback from the market are very strong."
Under the co-promotion agreement between Paladin and Nycomed, Nycomed will share brand responsibilities and expenses with Paladin and will deploy a national primary care sales force to promote Tridural(TM). Paladin will continue to manage distribution of Tridural(TM) and will also continue to promote Tridural(TM) using its primary care sales force.
Labopharm entered into a licensing and distribution agreement for its once-daily tramadol product for Canada with Paladin in July 2007. Paladin subsequently launched the product to the Canadian market in September 2007.
About Tridural(TM)
Tridural(TM) is a unique treatment option developed as a first-line
therapy for adult patients with moderate pain who require treatment for
several days or more that provides 24-hour pain relief from a single tablet
taken once-daily. Tridural(TM) is based on Labopharm's proprietary
controlled-release technology, Contramid(R), and a novel dual matrix
delivery system that facili
'/>"/>
| SOURCE Labopharm Inc. Copyright©2008 PR Newswire. All rights reserved |